Ensysce Biosciences Initiates PF614 Phase 3 Enrollment, Advances Opioid Towards Commercialization

• Ensysce Biosciences initiated PF614 Phase 3 enrollment for opioid treatment. • PF614 is a next-generation opioid for moderate to severe pain. • Ensysce Biosciences is advancing PF614 towards commercialization. • The company announced the first patient enrollment in PF614-301 Phase 3 study. • Ensysce Biosciences is a leading equity research firm focusing on small cap public companies. • The update note includes information on the company's business updates, management commentary, financial results, valuation, and risks.